Novartis (VTX:NOVN) Given a CHF 78 Price Target at JPMorgan Chase & Co.

Novartis (VTX:NOVN) has been assigned a CHF 78 price objective by equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday, June 5th, Borsen Zeitung reports. The firm currently has a “sell” rating on the stock.

A number of other equities analysts also recently weighed in on NOVN. Deutsche Bank set a CHF 93 target price on shares of Novartis and gave the stock a “neutral” rating in a research note on Tuesday, February 5th. HSBC set a CHF 86 target price on shares of Novartis and gave the stock a “neutral” rating in a research note on Wednesday, February 6th. UBS Group set a CHF 89 target price on shares of Novartis and gave the stock a “neutral” rating in a research note on Monday, March 4th. Goldman Sachs Group set a CHF 110 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Monday, March 25th. Finally, Jefferies Financial Group set a CHF 105 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Wednesday, March 27th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of CHF 89.18.

Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: What does a neutral rating on stocks mean?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.